 

Active Ingredient: Acetaminophen; Butalbital; Caffeine; Codeine phosphate 

 

Dosage Form; Route: Capsules; oral 

 

Recommended Studies: Two studies 

 

1. Type of study: Fasting 


Design: Single-dose, two-way crossover in vivo 

Strength: 325 mg; 50 mg; 40 mg; 30 mg 

Subjects: Healthy males and nonpregnant females, general population. 

Additional comments: None 

 

 

2. Type of study: Fed 


Design: Single-dose, two-way crossover in vivo 

Strength: 325 mg; 50 mg; 40 mg; 30 mg 

Subjects: Healthy males and nonpregnant females, general population. 

Additional comments: None 

 

 

Analytes to measure (in appropriate biological fluid): Butalbital and codeine in plasma 

 

Bioequivalence based on (90% CI): Butalbital and codeine 

 

Waiver request of in vivo testing: Not applicable N/A 

 

Dissolution test method and sampling times: The dissolution information for this drug product 
can be found on the FDA-Recommended Dissolution Methods website available to the public at 
the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. Conduct 
comparative dissolution testing on 12 dosage units each of all strengths of the test and reference 
products. Specifications will be determined upon review of the abbreviated new drug application 
(ANDA). 

 

 

 


